Comparison of video-assisted thoracoscopic surgery and standard surgical approach in treatment malignant thymus tumor stage I and II – propensity score analysis

Поредњење видеасистиране торакоскопске хирургије и стандардног хируршког приступа у лечењу малигних тумора тимуса I и II стадијума – анализа „пропензити скором“

1 Military Medical Academy, Clinic for Thoracic and Cardiac Surgery, Belgrade, Serbia;  
2 Military Medical Academy, Clinic for Cardiology, Belgrade, Serbia;  
3 Clinical Centre Kragujevac, Clinic for General and Thoracic Surgery, Kragujevac, Serbia

Received: July 16, 2019  
Revised: June 8, 2020  
Accepted: June 10, 2020  
Online First: June 19, 2020  
DOI: https://doi.org/10.2298/SARH190716038K

† Correspondence to:  
Milena PANDRC  
Crnotravska 17, 11000 Belgrade, Serbia  
E-mail: pandrcmilena@yahoo.com
Comparison of video-assisted thoracoscopic surgery and standard surgical approach in treatment malignant thymus tumor stage I and II – propensity score analysis

INTRODUCTION

Thymus carcinomas belong to the group of epithelial tumors of the thymus, mainly located in the anterior mediastinum [1]. They are part of the group of rare and invasive malignancies and make up to 1.5% of all malignant tumors, and only 0.06% of all tumors of

SUMMARY

Introduction/Objective Besides sternotomy, video-assisted thoracoscopic surgery (VATS) is used for treatment of thymus tumors. The objective of our study is to compare oncological and perioperative outcomes in patients with I-II stage of thymic tumors treated with video-assisted thoracoscopic surgery or standard sternotomy procedures.

Method: The study included only primary I-II thymoma according to the Masaoka classification treated between May 2006 and February 2018. Out of 116 treated patients that had pathohistologically verified stage, 100 (86.2%) were matched by propensity score for sex, age, body mass index, myasthenia, tumor size, Masaoka classification stage. Oncological (direct post-operative survival, recurrence) and perioperative outcomes (intra and postoperative complications, length of hospitalization) that affect the efficacy and safety of surgical techniques have been analyzed and compared between the two groups.

Results: Among 50 patients operated by VATS, 34 patients (68%) were treated by uniportal approach, 13 (26%) by biportal and three (6%) by threeportal approach. The VATS intervention had shorter intervention time (p < 0.001), duration of hospitalization (p < 0.001), and usage of thoracic drainage (p < 0.001). There was a significant difference in terms of late control (p < 0.001). There was no significant difference between the groups in terms of the time of recurrence (p = 0.305, p = 0.268).

Conclusion: Compared to standard sternotomy, VATS thymectomy is an equally effective and significantly safer method with a minimum rate of intra and postoperative complications.

Keywords: thymoma, video assisted thoracoscopy, open thymectomy

SAŽETAK

Увод/Циљ. Хируршко лечење тумора тимуса (тимектомија) се може спровести кроз стернотомни приступ или видеасистираном торакоскопском хирургијом (VATS). Циљ студије је да упореди онколошке и периоперативне исходе (интра и постоперативне компликације, дужину хоспитализације) у пацijената са I-III стадијумом тумора тимуса леченih VATS методом или стандардном тимектомијом.

Метод. Студија је обухватала pacijente са примарним тумором тимуса леченом VATS методом или стандардном стернотомијом. Онколошки и периоперативни исходи који утичу на ефикасност и безбедност хируршке технике су упоређени између две групе.

Резултати: Од 50 пацијената оперисаних VATS-ом, у 34 пацијенту (68%) је примењен унипортални приступ, у 13 пацијенту (26%) бипортални, а у три пацијента (6%) трипортални приступ. VATS операција је значајно краће трајала (p < 0.001), захтевала краћу хоспитализацију (p < 0.001) и употребу дrena (p < 0.001). Оперисани VATS-ом су се касније јавили (p < 0.001). Није било разлике у погледу VATS скора као ни у погледу времена настанка рецидива између испитиваних група (p = 0.305, p = 0.268).

Заключак: VATS тимектомија је подједнако ефикасна и значајно безбеднија метода са минимальном стопом интра и постоперативних компликација у односу на стандардну стернотомију.

Кључне речи: тимом, видео асистирана торакоскопија, отворена тимектомија

INTRODUCTION

Thymus carcinomas belong to the group of epithelial tumors of the thymus, mainly located in the anterior mediastinum [1]. They are part of the group of rare and invasive malignancies and make up to 1.5% of all malignant tumors, and only 0.06% of all tumors of
thymus in general [1, 2]. They most commonly occur between the age of 30 and 60, but they can also occur in early childhood and elderly life, without significant predilection by gender [2, 3]. It is important to underline that a few patients have systemic symptoms including autoimmune disease [4]. Approximately 30% of patients with thymoma have myasthenia gravis [5]. Post-thymectomy myasthenia gravis is registered in around 1–3% of the operated patients, and this disorder even progresses after extensive thymectomy mostly characterized for open surgery [5, 6, 7].

In surgery, Masaoka-Koga staging system is commonly used as the most important determinant of long-term prognosis after surgical resection [8]. Resection / surgery is the first and most important modality for treating tumors of the thymus; the possibility of implementing a complete resection is the most important parameter that defines a long-term prognosis [9, 10]. The rate of relapse ranges from 1-5% for non-invasive to 20% for invasive complete resective tumors [11, 12]. There are controversial attitudes considering surgery, surgical approach, the place of thoracoscopic methods, and the extent of thymoma resection [4].

Nowadays, the most thymoma patients indicate VATS surgery in Military Medical Academy. Numerous reports show that patients with Masaoka stage I–II thymoma underwent VATS [4,12]. The minimally invasive approach is the recommended option in the I-II stage of the tumor, while for stage III there are no data on long-term survival of the patients, so that open surgery is represented as a therapeutic approach [8, 13-16]. The invasion to the innominate vein, phrenic nerve, or other major vessels should be a contraindication to VATS [13]. It is widely accepted that VATS is technically safe and feasible for thymomas with a diameter <50 mm [14]. VATS mostly includes unipolar technique by one-sided approach (right or left side) with respect to the anatomical localization of the thymus. The right –side approach is more secure because of the relationship with the brachiocephalic vein [4].
Although the definitive guidelines have not yet been established regarding the extent of thymoma resection, it is well known that extensive resection of the thymus may increase the potential risk of the intra and post-operative complications [4].

By developing minimally invasive surgery, video-assisted thoracoscopic surgery (VATS) is imposed as an excellent alternative to sternotomy procedures [1, 16, 17]. However, the safety of VATS and the achievement of a complete stable remission as an efficiency measure and evaluation criterion in assessing the radicality of resection remain insufficiently examined, since most of the previously cited studies, as well as the studies included in the aforementioned analysis, encompassed a relatively small number of patients.

The study was based on analysis and comparison of oncological outcomes (direct post-operative survival, recurrence), as well as analysis and comparison of the type and frequency of perioperative outcomes (intra and postoperative complications, duration of hospitalization) in patients with I-II stage of thymic tumors treated with video-assisted thoracoscopic surgery and standard sternotomy procedures.

**METHODS**

The retrospective cohort study included 156 patients with primary thymus tumors, operated in Clinic for thoracic and cardiac surgery in the period from 2006 to 2018. Criteria for exclusion from the study were: incomplete medical documentation (56 patients or 20%), comorbidities that did not allow anesthesia (25 patients or 8.92%), advanced malignant disease (35 patients or 12.5%), coagulopathy (six patients or 2.14%), alcoholism (one patient or 0.36%) and the use of psychoactive substances (one patient or 0.36%). A total of 116 treated patients have the pathohistologically verified stage I-II thymoma according to the Masaoka classification. The remaining 40 patients or 14, 4% either died because of
complication during the intervention (four patients or 1.44%) or had a stage III-IV thymoma according to the Masaoka classification (36 patients or 12.96%).

Using propensity score based on six variables (sex, age, body mass index, myasthenia, tumor size, Masaoka classification stage) each patient in the VATS-treated group was "matched" with a patient in a group treated with a standard thymectomy with the same propensity score. Of total number of patients included in study (116), 100 patients (86.2%) were matched, resulting in the formation of two identical groups with similar sociodemographic and clinical features (Figure 1).

All epidemiological (sex, age) and anthropometrical data (height, body mass, body mass index derived as: body mass/height²(kg/m²)) were recorded in medical documentation, as well as the number comorbidities and the Charlson Comorbidity Index. In hospital medical abstracts we have also found the data considering comedications (number of drugs and daily doses of drugs) and tumor size.

Among 156 patients underwent surgery, 98 patients (62.8% of the operated) were treated with standard thymectomy. Those from the group who survived the intervention and had the stage I-II thymoma according to the Masaoka classification, were included in matching (58 patients or 59% of all treated with standard procedure, or 37.5% of all surgery patients).

Since 2012, VATS thymectomy has become a standard surgical technic for thymectomy. VATS technic by one-sided approach (to the right or left side) respects to the anatomical localization of the thymus. All patients treated with VATS were familiar with the surgical approach, potential risks, and complications, and they signed a standardized consent at the Military Medical Academy.
All procedures performed in study involving human participants were in accordance with the ethical standards of the Ethical Commission of Belgrade University of Defence (Ethical Approval from October 30th 2018)

Oncological and perioperative outcomes (intraoperative and postoperative) that affect the efficacy and safety of surgical techniques have been analyzed and compared between the two groups. The following variables were included: duration of the surgical intervention, the length of hospitalization and thoracic drainage, the late control, recurrence.

The first control was after the month from the surgery. The patients had the thorax MSCT done before the control. After six month, they also were checked by the operator and neurologist. The late control is the next control after 6th month control, regularly planned for the 12th month after the intervention, but it occurred early if the patient has some late complication of the intervention (intercostal neuralgia, psychiatric problems linked with the treatment, neurological exacerbation). The time of the late control was expressed in months. Initially, the patient was checked by the operator, who indicated the next procedures and consultations. The VAS scale (visual analog scale) was used for evaluation of post-surgical pain.

Complete statistical analysis of data was made using commercial statistical software SPSS Statistics 18. In the case of continuous variables, the data are presented as median, min-max and IQR (25th -75th percentile). The distribution of data was checked using the Shapiro-Wilk test. Depending on the results of this test, statistical significance between the groups was tested using a t-test for independent groups or alternatively Mann-Whitney test. Some variables are presented in the form of frequencies of particular features (categories) and statistical significance will be determined using the Chi squared test. A statistically significant difference is assessed at the minimum level p <0.05.
RESULTS

Of the total number of patients included in the study (116), 100 patients (86.2%) were matched. There was no statistically significant difference in distribution in terms of sex between two groups (p = 0.316). The study results did not show significant difference in distribution and type of comorbidities between the groups. The most frequent associated disease in each group was hypertension (VATS vs thoracotomy: 16% vs. 18%, p = 1.000) (Table 1 and 2).

There was no statistically significant difference in age (p = 0.588), body mass index (p = 0.424), number of comorbidities and Charlson’s Comorbidity index (p = 0.735 and p = 0.828 successively), number of drugs (p = 0.676) and tumor size (p = 0.566) between the group treated with VATS and the group treated with standard technique (Table 2). There was no statistically significant difference in the daily dose of drugs (pronison, Imuran, proton pump inhibitors (IPP), vitamin D (Alpha D3), CaCO3) between the groups (successively p = 0.597, p = 0.111, p = 0.832, p = 0.664, p = 0.664) (Table 3).

Among the 50 patients treated with VATS, uniportal approach was used in 34 patients (68%), biportal in 13 patients (26%) and threeportal in 3 patients (6%).

The duration of VATS intervention was significantly shorter compared to the standard intervention, as well as hospitalization stay and thoracic drainage (p < 0.001, p < 0.001, p < 0.001). All the patients achieved the late control, but the thoracotomy- treated patients came significantly earlier (11 months vs. 12 months after the surgery, p < 0.001). The patients underwent thoracotomy who came earlier to the late control (5 patients or 10% thoracotomy - treated) had the intercostal neuralgia ( 2 patients or 4% thoracotomy - treated ), psychiatric problems linked with the treatment ( 1 patients or 2% thoracotomy - treated ) and neurological exacerbation ( 2 patients or 4% thoracotomy - treated ). There was no difference
regard to visual analog (VAS) score, as well as in the time of recurrence between the groups (p = 0.305, p = 0.268) (Table 4).

DISCUSSION

Our study results obtained from the analyzing and comparing oncological and perioperative outcomes of the VATS thymectomy and standard thoracotomy support VATS as the recommended approach in the I-II stage of the thymus tumor.

Consistently with our results is the recommendation VATS technic as a "golden standard" for the I-II stage of the tumor [9, 14-16]. For III-IV thymoma there are no data on long-term survival of the patients, so that open surgery is suggested as a therapeutic approach [9, 14-16]. Based on the previous cited recommendations and ethical principles, our study design did not include stage III-IV thymoma, also excluding other comorbidities' influence upon treatment decision among study patients.

Numerous studies confirm the equal efficacy of VATS thymectomy compared to standard sternotomy, comparable radicality and long-term survival, with a better cosmetic effect, lower intensity of postoperative pain and blood loss, reduced hospitalization time, lower early and late postoperative morbidity [7, 16-30].

Besides thymomas, some study data referred the importance of VATS surgery in myasthenia gravis treatment. Thymectomy in patients with myasthenia gravis supported stable clinical course, leading to clinical remission and reduce the dose of comedication used in conservative treatment [7]. A 12-year study that monitored the long-term efficacy of VATS thymectomy as part of the treatment of non-myomatosal myasthenia gravis suggests an improvement in 91.6% of surgical cases and a stable remission of 22.2% [18]. There was no measurable difference between the study groups in the daily dose of comedication used in conservative treatment of myasthenia gravis and its side effects (osteoporosis, acute gastritis),
supporting previous data considering comparable radicality. It seems to be important, having in mind that post-thymectomy myasthenia gravis is reported in almost 3% of the operated patients, mostly after standard procedure [5-7].

Assessing efficacy through the mass of the removed tissue, Lee and al. state that there is no difference between VATS and open surgery in terms of radicality of the procedure [19]. Comparable oncological outcomes also refer to Ye and al. [20]. Wang and al. report that there is no difference in terms of a five-year survival between the patients subjected to VATS and open surgery as part of the treatment of thymoma [21]. The same conclusions arise from the studies of Chao and al., as well as Qi and al. [22-23].

Zahid and al. point out the equivalent postoperative mortality and achieve a stable remission of VATS compared to open surgery. Also, their study results highlight the superiority of VATS in terms of duration of hospitalization, bleeding, cost of surgery, intensity of pain, and cosmetic effect [24-27]. Ashleigh and al. in meta-analysis underlined the results that are consistent with the referred data [25]. Our study data supported previous cited reports considering duration of VATS procedure and hospitalization, thoracic drainage, with the equal intensity of pain objectified by VAS scale. Also, recurrences occur with a frequency between 0 and 6.7%, which is comparable to open timectomy [15, 26-27]. The recently published meta-analysis, which involved about 1200 patients, points out that VATS is superior in terms of safety (lower incidence of complications and myasthenic crises) compared to open surgery and equally effective in achieving a complete stable remission [28].

Our results are in accordance with previous referred study findings, especially in the term of late control. The group treated with VATS had the third (late) control later than the group treated with standard thymectomy because they had less complications with the comparable time of recurrence.
The first VATS thymectomy in Serbia applied in 2012. Military Medical Academy data referred 70 VATS thymectomies done by three-, two-, and uniportal approach until the end of 2018 [7]. With the improvement of surgical technique, VATS uniportal approach becomes standard and dominant in the Clinic for Thoracic Surgery of the Military Medical Academy in the treatment of stage I – II thymus tumors.

Our study, involving 116 patients, presents a respectable contribution to the further analysis of clinically significant data on VATS thymectomy as an alternative operating pathway for treating I-II patients with thymic tumor compared to standard thymectomy. Results obtained in this study indicate the benefit of VATS thoracoscopy compared to standard thymectomy, which is reflected in greater safety and equal or greater efficacy of VATS, as well as in a lower incidence of postoperative complications and faster recovery. VATS thymectomy is far less invasive and represents an equally effective solution compared to standard sternotomy. Postoperative is a low intensity pain, scar is small. Also, the intervention itself can be well presented and documented. Recovery is significantly shorter, and the costs of treatment are lower. The length of home treatment and absence from work is also significantly shorter in patients treated with VATS. Possible complications of VATS thymectomy, such as intercostal neuralgia, psychiatric problems linked with the treatment, neurological exacerbation, are the same as those in alternative methods of thymectomy, but with less frequency.

Limitations of our study are retrospective character of the study and great number of excluded patients due to restrictive inclusion criteria.

CONCLUSION

Compared to standard sternotomy, VATS thymectomy is an equally effective and significantly safer method with a minimum rate of intra and postoperative complications. Our
findings support previous study results considering VATS thymectomy as a golden standard for malignant thymus tumour (stage I and II). Further study on the greater numbers of participants would be necessary to define the effectiveness of VATS surgery for the stage III-IV thymoma according to the Masaoka classification.

Limitation of the study

Limitations of our study are retrospective character of the study and great number of excluded patients due to restrictive inclusion criteria.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethical Commission of the University of Belgrade, Faculty of Medicine, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All procedures performed in study involving human participants were in accordance with the ethical standards of the Ethical Commission of Belgrade University of Defence (Ethical Approval from October 30th 2018) Informed consent was obtained from all individual participants included in the study.

ACKNOWLEDGMENTS

This work was not financed nor funded.

Conflict of interest: None declared.
REFERENCES


7. Martić V, Marić N, Cvijanović V. The neurological outcome of patients with myasthenia gravis underwent thymectomy via sternotomy and video assisted thoracoscopic surgery (VATS). Vojnosanit Pregl. 2020; doi: 10.2298/VSP190715133M.


**Figure 1.** Design of the study

**Inclusion criteria:** patients with primary thymus tumors, treated in Clinic for thoracic and cardiac surgery in the period from 2006 to 2018.

**Exclusion criteria:** incomplete medical documentation (56 pts or 20%), comorbidities that did not allow anesthesia (25 pts or 8.92%), advanced malignant disease (35 pts or 12.5%), coagulopathy (6 pts or 2.14%), alcoholism (1 pt or 0.36%), the use of psychoactive substances (1 pt or 0.36%).

40 pts or 14.4% either died because of complication during the intervention (intra and pericranium) (4 pts or 1.44%) or had a stage III-IV thymoma according to the Masaoka classification (36 pts or 12.96%).

Using propensity score based on 6 variables (sex, age, body mass index, myasthenia, tumor size, Masaoka classification stage). Patients were matched: 16 pts or 5.76% did not match.

End of the study
Table 1. Gender and comorbidities of the study population

<table>
<thead>
<tr>
<th>Parameters</th>
<th>VATS n = 50</th>
<th>Thoracotomy n = 50</th>
<th>p values*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender: Male</td>
<td>30 (55.6%)</td>
<td>24 (44.4%)</td>
<td>0.316</td>
</tr>
<tr>
<td>Gender: Female</td>
<td>20 (43.5%)</td>
<td>26 (56.5%)</td>
<td>0.316</td>
</tr>
<tr>
<td>Comorbidities (no/yes)</td>
<td>40(80.00)/10(20.00)</td>
<td>41(82.00)/9 (18.00)</td>
<td>1.000</td>
</tr>
<tr>
<td>Hypertension (no/yes)</td>
<td>42(84.00)/8 (16.00)</td>
<td>41(82.00)/9 (18.00)</td>
<td>1.000</td>
</tr>
<tr>
<td>Iron deficiency (no/yes)</td>
<td>50(100.00)/-</td>
<td>49(98.00)/ 1 (2.00)</td>
<td>1.000</td>
</tr>
<tr>
<td>Diabetes mellitus (no/yes)</td>
<td>48 (98.0)/ 2 (4.0)</td>
<td>50 (100)/ -</td>
<td>0.495</td>
</tr>
<tr>
<td>Ischemic brain disease (no/yes)</td>
<td>49 (98.0)/ 1 (2.0)</td>
<td>50 (100)/ -</td>
<td>1.000</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease (no/yes)</td>
<td>48 (98.0)/ 2 (4.0)</td>
<td>50 (100)/ -</td>
<td>0.495</td>
</tr>
<tr>
<td>Chronic kidney disease (no/yes)</td>
<td>49 (98.0)/ 1 (2.0)</td>
<td>50 (100)/ -</td>
<td>1.000</td>
</tr>
<tr>
<td>Hypertrophio prostatae benigna (no/yes)</td>
<td>49 (98.0)/ 1 (2.0)</td>
<td>49 (98.0)/ 1 (2.0)</td>
<td>1.000</td>
</tr>
<tr>
<td>Other diseases (no/yes)</td>
<td>47 (94.0)/ 3 (6.0)</td>
<td>50 (100)/ -</td>
<td>0.242</td>
</tr>
</tbody>
</table>

* χ² test; data are presented as the absolute numbers (%)
Table 2. Epidemiological and clinical features of the patients treated with VATS and standard surgery

<table>
<thead>
<tr>
<th>Epidemiological and clinical characteristics of the patients</th>
<th>VATS n = 50</th>
<th>Thoracotomy n = 50</th>
<th>p values*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>39.50 (27-59.25)</td>
<td>39.50 (33.00-55.75)</td>
<td>0.588</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>23.90 (22.50-26.4)</td>
<td>24.21 (22.70-26.80)</td>
<td>0.424</td>
</tr>
<tr>
<td>Number of comorbidities</td>
<td>0.00 (0.00-0.00)</td>
<td>0.00 (0.00-0.00)</td>
<td>0.735</td>
</tr>
<tr>
<td>Charlson Comorbidity Index</td>
<td>0.00 (0.00-0.00)</td>
<td>0.00 (0.00-0.00)</td>
<td>0.828</td>
</tr>
<tr>
<td>Number of drugs</td>
<td>0.00 (0.00-2.25)</td>
<td>0.00 (0.00-2.00)</td>
<td>0.676</td>
</tr>
<tr>
<td>Tumor size (mm)</td>
<td>60.00 (50.00-80.00)</td>
<td>60.00 (50.00-95.00)</td>
<td>0.566</td>
</tr>
</tbody>
</table>

Data are presented as median (IQR - 25th-75th percentile);  
* Mann–Whitney test
Table 3. Comedication in the group treated with VATS and with the open surgery

<table>
<thead>
<tr>
<th>Comedication</th>
<th>VATS n = 50</th>
<th>Thoracotomy n = 50</th>
<th>p values*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pronison (mg)</td>
<td>0.00 (0.00-20.00)</td>
<td>0.00 (0.00-20.00)</td>
<td>0.597</td>
</tr>
<tr>
<td>Imuran (mg)</td>
<td>0.00 (0.00-0.00)</td>
<td>0.00 (0.00-0.00)</td>
<td>0.111</td>
</tr>
<tr>
<td>Proton pump inhibitors –IPP (mg)</td>
<td>0.00 (0.00-40.00)</td>
<td>0.00 (0.00-40.00)</td>
<td>0.832</td>
</tr>
<tr>
<td>Vitamin D-Alpha D3 (mcg)</td>
<td>0.00 (0.00-50.00)</td>
<td>0.00 (0.00-50.00)</td>
<td>0.664</td>
</tr>
<tr>
<td>Number of drugs</td>
<td>0.00 (0.00-5.00)</td>
<td>0.00 (0.00-5.00)</td>
<td>0.664</td>
</tr>
</tbody>
</table>

Data are presented as median (IQR - 25th-75th percentile); * Mann-Whitney test
Table 4. Surgical outcomes compared between the patients treated with VATS and with open thymectomy

| Surgical outcomes                      | VATS  
|----------------------------------------|--------|
|                                        | n = 50 | Thoracotomy  
|                                        |        | n = 50 | p values* |
| Duration of operation (min)            | 50.00 (45.00–60.00) | 120.00 (90.00–150.00) | < 0.001 |
| Duration of hospitalisation (days)     | 4.00 (3.00–6.00) | 9.00 (7.00–10.25) | < 0.001 |
| Thoracic drainage (days)               | 2.00 (1.00–3.00) | 4.00 (3.00–5.00) | < 0.001 |
| Late control (months)                  | 12.00 (12.00–12.00) | 11.00 (9.00–12.00) | < 0.001 |
| VAS score (0-10)                       | 2.00 (1.00–3.00) | 2.00 (2.00–3.00) | 0.305 |
| Recurrence time (months)               | 0.00 (00.00–00.00) | 0.00(0.00–1.50) | 0.268 |

Data are presented as median (IQR - 25th-75th percentile); * Mann–Whitney test